Company Announcements

Appointment of New Director

Source: RNS
RNS Number : 0897Z
BioPharma Credit PLC
16 September 2020
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

Appointment of New Director

 

The Company is pleased to announce the appointment of Rolf Soderstrom as a non-executive Director, with effect from 16 September 2020.

 

Rolf has over 30 years' strategic and operational experience in finance including M&A, fundraisings and disposals and is currently Senior Independent Director of Ergomed plc and Chair of its Audit and Risk Committee and External Independent Director of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange, both of which are companies in the life sciences sector. From 2008 to 2018, Mr Soderstrom was CFO of BTG plc and helped drive the successful transformation of the company into a fully integrated global manufacturing and sales organisation focused on specialist healthcare. He was previously Divisional Finance Director at Cobham Plc and Director of Corporate Finance at Cable & Wireless Plc and qualified as a chartered accountant at PricewaterhouseCoopers.

 

Publicly quoted directorships held by Mr Soderstrom within the last five years are as follows:

 

Company 

 

Position

Sosei Group Corporation

 

External Independent Director and member of audit committee

 

Ergomed plc

 

Non-executive Director, Senior Independent Director, Chair of the Audit and Risk Committee and member of Remuneration and Nomination Committees

 

BTG plc

Chief Financial Officer

 

                                        

There are no other details required to be disclosed under LR 9.6.13R (2) to (6) of the Financial Conduct Authority Listing Rules.

 

 

16 September 2020

 

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFZGMLVKNGGZM